Aggregated from the cited literature below. We summarize sources — we don't author claims.
Pramlintide is a synthetic analogue of the human hormone amylin and is described as an amylinomimetic compound. Review literature reports that it is used clinically as an adjunct to insulin therapy for type 1 and type 2 diabetes, and that amylin agonists (including pramlintide) have been investigated for potential weight-loss effects in obesity research, including in combination with other agents. (PMIDs: 26071095, 16278328, 34288673, 30000033, 39317404)
Mechanism (as reported)
A review describes amylin as activating specific multisubunit G protein-coupled receptors (with multiple receptor subtypes) and functioning in glucoregulatory energy metabolism and other reported organ-system effects. (PMID: 26071095) A pramlintide-focused review reports that pramlintide complements insulin’s effects in postprandial glucose regulation by decreasing glucagon secretion; it is also reported to slow gastric emptying and reduce postprandial glucose levels. (PMID: 16278328)
Key findings (each cites a source)
Pramlintide is described as a synthetic analogue of the human hormone amylin and as an amylinomimetic compound. (PMID: 16278328) [PMID 16278328]
Amylin is described as a 37-amino-acid peptide that activates specific multisubunit G protein-coupled receptors, resulting in multiple receptor subtypes. (PMID: 26071095) [PMID 26071095]
A review reports that pramlintide is used clinically to treat type 1 and type 2 diabetes. (PMIDs: 26071095, 16278328) [PMID 26071095, 16278328]
A review reports that pramlintide is used as an adjunct to insulin therapy for patients with diabetes who have failed to achieve glycemic control despite optimal insulin therapy. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide decreases glucagon secretion and complements insulin’s effects in postprandial glucose regulation. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports pramlintide slows gastric emptying and reduces postprandial glucose levels. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide is predominantly renally eliminated and has a mean elimination half-life of about 30–50 minutes. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports an increased risk of insulin-induced severe hypoglycemia, along with adverse events such as nausea, anorexia, fatigue, and vomiting. (PMID: 16278328) [PMID 16278328]
A review reports that clinical studies in obesity indicate amylin agonists (including pramlintide) could be useful for weight loss, especially in combination with other agents. (PMID: 26071095) [PMID 26071095]
A source describing amylin analogs for obesity reports that pramlintide has demonstrated weight-lowering action and that clinical trials confirmed weight loss exceeding 3% during the study period, maintained beyond follow-up, without major untoward effects (as characterized in that source). (PMID: 39317404) [PMID 39317404]
A source on longer-acting amylin analogue development reports that pramlintide is commercially available for diabetes treatment but requires three daily injections due to short half-life, motivating development of a longer-acting analogue (cagrilintide). (PMID: 34288673) [PMID 34288673]
Independent test grades
No independent third-party test data is available for Pramlintide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (11)
Consolidated from PubMed — each links to the original record.
McQueen J · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2005 · PMID 16278328
FAQ
What is Pramlintide?
Pramlintide (Triproamylin, pramlintida, TRIPRO-AMYLIN) is classified under amylin analogs, an FDA-approved drug. Research goals associated with it include metabolic & weight.
Is Pramlintide FDA-approved?
Yes — Pramlintide is approved by the FDA (marketed as Triproamylin, pramlintida).
What does the research on Pramlintide say?
peptideone aggregates 11 references from PubMed for Pramlintide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.